TY - JOUR T1 - A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate JF - Anticancer Research JO - Anticancer Res SP - 3303 LP - 3310 VL - 24 IS - 5C AU - TORU KANEKO AU - SHIGENORI GOTO AU - YOSHIAKI KUSHIMA AU - YOJU MIYAMOTO AU - MASAZUMI ERIGUCHI AU - MIE NIEDA AU - KOJI EGAWA Y1 - 2004/09/01 UR - http://ar.iiarjournals.org/content/24/5C/3303.abstract N2 - Background: Immunocell therapy has been applied to patients with refractory cancer in clinical trials or as an unconventional cancer therapy, however the efficacy is still limited. To improve this efficacy, a combination therapy may be beneficial. Molecularly-targeted therapy acts directly on neoplasm cells to suppress their growth without causing myelosuppression. Case Report: Recently, we encountered three patients treated by immunocell therapy with imatinib mesylate (GlivecĀ®). One patient was diagnosed as having Philadelphia chromosome (Ph) (+) acute lymphoblastic leukemia (ALL) and had a relapse-free survival of more than 24 months. The other two were diagnosed as having GIST; a partial response was observed in one which lasted more than 21 months, while the other's disease has been stabilized for more than 25 months. No side-effects were observed, other than those mentioned in the directions for the use of imatinib. Conclusion: Immunocell therapy may have a potent therapeutic effect when used in combination with molecularly-targeted therapy, which has few side-effects. ER -